IVI’s Lakdawalla in WSJ: Look to Major League Baseball for Drug Pricing Insight
In a new commentary appearing in The Wall Street Journal, Dana Goldman and IVI Executive Director, Darius Lakdawalla, turn to the national pastime to provide a fresh perspective on the issue of drug pricing and the return on investment pharmaceutical companies need to sustain innovation. In baseball, the salaries are high and the talent pool is […]
Discussing Value-Based Payments in Oncology
Dana Goldman, Darius Lakdawalla (Executive Director of IVI), and Lee Newcomer argue for an updated value-based payment system in oncology in the latest edition of the Health Affairs blog. Read the full article here.
Time to Dig Deeper When Evaluating Value In Healthcare
In Tomas Philipson’s latest Forbes.com op-ed, he and co-author Anupam Jena suggest it is time to stop scratching the surface when it comes to value in healthcare. Read the full article here.
Addressing Value Frameworks
Amitabh Chandra, Jason Shafrin (IVI Director of Research), and Ravider Dhawan examine the utility of cancer value frameworks in the latest edition of the Journal of the American Medical Association (JAMA). Read the full abstract here.
Discussing Access and Pricing for Generic Drugs
In a commentary for Modern Healthcare, Dana Goldman describes how access and pricing for generic drugs could be improved by taking a lesson from vaccine policy. Read the full article here.
Tackling the EpiPen Pricing Controversy
Dana Goldman addresses the firestorm created by Mylan’s dramatic price hikes for their EpiPen in a new commentary published in STAT News. Read the full article here.
Network Meta-Analysis Needed to Improve Clinical Oncology Value Framework
In his letter to the editor published in the Journal of Clinical Oncology, IVI’s Evidence Synthesis Expert, Jeroen Jansen, argues that network meta-analysis is the only transparent framework to help answer the treatment selection question. Responding to his letter, members of the ASCO Task Force reply that Dr. Jansen makes a “strong argument for the use […]
Discussing A Model for More Rational Drug Prices
IVI Executive Director, Darius Lakdawalla, is featured in the AP’s Big Story, discussing the need for a more rational drug pricing model. Read the full article here.
Responding to President Obama on the Affordable Care Act
Amitabh Chandra and co-author Jonathan Skinner respond to President Obama’s JAMA letter describing the success of the Affordable Care Act (ACA), concluding that, while the landmark legislation suffers from a number of fundamental problems, it is also “far more moderate, innovative — and difficult to replace — than its critics claim.” Read the full article […]
How New Value Frameworks Can Undermine the Ability of Patients and Providers to Find the Best Treatment
In Tomas Philipson’s latest Forbes.com op-ed, he and co-author Jason Shafrin (IVI Director of Research) describe the potential for new value frameworks to undermine the ability of patients and providers to find the best treatment for a specific patient. Read the full article here.